<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005625.pub3" GROUP_ID="PVD" ID="624604052514370996" MERGED_FROM="" MODIFIED="2015-09-15 13:32:29 +0100" MODIFIED_BY="Cathryn Broderick" REVIEW_NO="774" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2015-09-15 13:32:29 +0100" MODIFIED_BY="Cathryn Broderick">
<TITLE MODIFIED="2012-07-17 14:15:26 +0100" MODIFIED_BY="[Empty name]">Rutosides for treatment of post-thrombotic syndrome</TITLE>
<CONTACT MODIFIED="2015-09-15 13:32:29 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15759" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dinanda</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Kolbach</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>dinanda.kolbach@maastrichtuniversity.nl</EMAIL_1><EMAIL_2>dinanda@kolbachkliniek.nl</EMAIL_2><URL>www.kolbachkliniek.nl</URL><MOBILE_PHONE>0031620406894</MOBILE_PHONE><ADDRESS><ORGANISATION/><ADDRESS_1>Strijthagerweg 15</ADDRESS_1><CITY>Landgraaf</CITY><ZIP>6372 AC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 6 20406894</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-09-15 13:32:29 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="3E92EA9D82E26AA20164DA25B5787D76" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joanne</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Morling</LAST_NAME><POSITION>Diabetes UK Clinical Training Fellow</POSITION><EMAIL_1>j.morling@ed.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Population Health Sciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Medical Buildings</ADDRESS_1><ADDRESS_2>Teviot Place</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH8 9AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>0131 6503244</PHONE_1><PHONE_2>0778 986 8899</PHONE_2></ADDRESS></PERSON><PERSON ID="16127939507286096907101012125811" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Su Ern</FIRST_NAME><LAST_NAME>Yeoh</LAST_NAME><POSITION>Year 3 Medical Student</POSITION><EMAIL_1>ern_yeoh@hotmail.com</EMAIL_1><EMAIL_2>s0906061@sms.ed.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>College of Medicine and Veterinary Medicine</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><CITY>Edinburgh</CITY><ZIP>EH16 4TJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="15759" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dinanda</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Kolbach</LAST_NAME><POSITION>Dermatologist</POSITION><EMAIL_1>dinanda.kolbach@maastrichtuniversity.nl</EMAIL_1><EMAIL_2>dinanda@kolbachkliniek.nl</EMAIL_2><URL>www.kolbachkliniek.nl</URL><MOBILE_PHONE>0031620406894</MOBILE_PHONE><ADDRESS><ORGANISATION/><ADDRESS_1>Strijthagerweg 15</ADDRESS_1><CITY>Landgraaf</CITY><ZIP>6372 AC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 6 20406894</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-09-09 10:09:40 +0100" MODIFIED_BY="Cathryn  Broderick">
<UP_TO_DATE>
<DATE DAY="2" MONTH="9" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="9" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="9" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-09-09 10:09:53 +0100" MODIFIED_BY="Cathryn  Broderick">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-09-09 10:09:53 +0100" MODIFIED_BY="Cathryn  Broderick">
<DATE DAY="2" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>New search run. No studies identified. Minor text changes made, summary of findings table added. No change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-09-09 10:09:47 +0100" MODIFIED_BY="Cathryn  Broderick">
<DATE DAY="2" MONTH="9" YEAR="2015"/>
<DESCRIPTION>
<P>New search run. No studies identified. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-02-17 09:30:46 +0000" MODIFIED_BY="Marlene Stewart">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-17 09:30:46 +0000" MODIFIED_BY="Marlene Stewart">
<DATE DAY="3" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-08-27 14:05:47 +0100" MODIFIED_BY="Cathryn  Broderick">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-08-27 14:05:47 +0100" MODIFIED_BY="Cathryn  Broderick">
<SOURCE MODIFIED="2015-08-27 14:05:47 +0100" MODIFIED_BY="Cathryn  Broderick">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The Cochrane Vascular editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-09-15 13:31:24 +0100" MODIFIED_BY="Cathryn  Broderick">
<SUMMARY MODIFIED="2015-09-15 11:54:08 +0100" MODIFIED_BY="Cathryn  Broderick">
<TITLE MODIFIED="2012-07-17 11:38:27 +0100" MODIFIED_BY="[Empty name]">Rutosides for treatment of post-thrombotic syndrome </TITLE>
<SUMMARY_BODY MODIFIED="2015-09-15 11:54:08 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>
<B>Background</B>
</P>
<P>Blood clots in the veins of the leg are a common problem and are termed deep vein thrombosis (DVT). One in three patients with a DVT develops a complication known as post-thrombotic syndrome (PTS). This syndrome involves ongoing swelling of the affected leg, pain, cramps, burning or prickling, and itching. Darkening of the skin because of increased pigmentation and varicose veins, redness and skin irritation can also occur. At the current time the main way of treating PTS is to wear compression stockings. It is known however that patients frequently find the stocking uncomfortable and so they may prefer to take an oral medication to treat the problem. Rutosides are a herbal remedy which has been shown to be effective in other conditions affecting the veins (chronic venous insufficiency).</P>
<P>
<B>Study characteristics and key results</B>
</P>
<P>This review aimed to evaluate the existing literature to see if rutosides were effective at treating PTS. We also investigated whether there were any side effects from the treatment. We searched all existing databases for trials relating to the use of rutosides for the treatment of PTS following DVT (current until September 2015). Two review authors independently assessed the trials for inclusion and extracted results in line with our prescribed criteria. We found three suitable trials, with a total of 233 patients, and six unsuitable trials that were not included in the review.</P>
<P>The studies compared rutoside with placebo, rutoside with compression stockings alone or in addition to rutosides, and rutoside with an alternative venoactive therapy (hidrosmina). The included studies used different doses of rutosides (900 to 2000 mg/day). We found no clear evidence from these trials that treatment with rutosides improved symptoms and signs of PTS or, in one trial, that patients taking rutosides had more side effects than those using a placebo but this was not statistically significant. Occurrence of leg ulceration was not reported in any of the included studies. There was a 29% odds of an improvement in PTS in the rutoside treated group versus placebo or no treatment, and lower rates of improvement in PTS in the rutoside treated group when compared with compression stockings, but these were statistically non-significant. Lower rates of improvement in PTS were shown in the rutoside treated group when compared with an alternative venoactive remedy. More PTS deterioration was shown in the placebo or no treatment group when compared with rutosides but this was not statistically significant. Compared with compression stockings, rutosides showed higher odds of PTS deterioration but this was also not statistically significant.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Overall quality of the evidence, using the GRADE approach, was low or very low mainly due to the lack of both participant and researcher blinding. The quality of the evidence was further limited as only three small studies contributed to the review findings. A subjective scoring system was used to obtain the symptoms of PTS so it was important that the assessors were blinded to the intervention.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-15 11:52:38 +0100" MODIFIED_BY="Cathryn  Broderick">
<ABS_BACKGROUND MODIFIED="2015-07-03 09:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). However, it is not known whether rutosides are effective and safe in the treatment of PTS. This is an update of the review first published in 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-07-03 09:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness (improvement or deterioration in symptoms) and safety of rutosides for treatment of post-thrombotic syndrome (PTS) in patients with DVT compared to placebo, no intervention, elastic compression stockings (ECS) or any other treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-02 10:35:31 +0100" MODIFIED_BY="Karen Welch">
<P>For this update the Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched September 2015) and the Cochrane Register of Studies (CRS) (CENTRAL (2015, Issue 8)). Clinical trials databases were searched for details of ongoing and unpublished studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-08-27 13:50:04 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Two review authors (JM and DNK) independently assessed studies for inclusion. Studies were included to allow the comparison of rutosides versus placebo or no treatment, rutosides versus ECS, and rutosides versus any other treatment. Two review authors (JM and SEY) extracted information from the trials. Disagreements were resolved by discussion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-03-01 06:17:57 +0000" MODIFIED_BY="[Empty name]">
<P>Data were extracted using designated data extraction forms. The Cochrane risk of bias tool was used for all included studies to assist in the assessment of quality. Primary outcome measures were the occurrence of leg ulceration over time (yes or no) and any improvement or deterioration of post-thrombotic syndrome (yes or no). Secondary outcomes included reduction of oedema, pain, recurrence of deep venous thrombosis or pulmonary embolism, compliance with therapy, and adverse effects. All of the outcome measures were analysed using Mantel-Haenzel fixed-effect model odds ratios. The unit of analysis was the number of patients.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-15 11:52:38 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Ten reports of nine studies were identified following searching and three studies with a total of 233 participants met the inclusion criteria. Overall quality of the evidence using the GRADE approach was low or very low, predominantly due to the lack of both participant and researcher blinding in the included studies. The quality of the evidence was further limited as only three small studies contributed to the review findings. A subjective scoring system was used to obtain the symptoms of PTS so it was important that the assessors were blinded to the intervention. One study compared rutoside with placebo, one study compared rutosides with ECS and rutosides plus ECS versus ECS alone, and one study compared rutosides with an alternative venoactive remedy. Occurrence of leg ulceration was not reported in any of the included studies. There was a 29% odds of an improvement in PTS in the rutoside treated group versus placebo or no treatment, and lower rates of improvement in PTS in the rutoside treated group when compared with ECS, however these were statistically non-significant. Lower rates of improvement in PTS were shown in the rutoside treated group when compared with an alternative venoactive remedy. More PTS deterioration was shown in the placebo or no treatment group when compared with rutosides but this was not statistically significant. Compared with ECS, rutosides showed higher odds of PTS deterioration but this was also not statistically significant. One study reported on adverse effects showing higher odds of mild adverse effects in the rutoside treated group compared to placebo but this was not statistically significant.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-09-09 10:10:57 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>There was no evidence that rutosides were superior to the use of placebo or ECS. Overall, there is currently limited and low or very low quality evidence that 'venoactive' or 'phlebotonic' remedies such as rutosides reduce symptoms of PTS. Mild side effects were noted in one study. The three studies included in this review provide no evidence for the use of rutosides in the treatment of PTS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-15 13:23:33 +0100" MODIFIED_BY="Cathryn  Broderick">
<BACKGROUND MODIFIED="2015-09-09 10:20:41 +0100" MODIFIED_BY="Cathryn  Broderick">
<CONDITION MODIFIED="2015-09-09 10:20:41 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by chronic complaints, swelling, and skin changes in the affected limb. One in every three patients with deep vein thrombosis will develop post-thrombotic sequelae within five years (<LINK REF="REF-Prandoni-1996" TYPE="REFERENCE">Prandoni 1996</LINK>). Although there is no gold standard for the diagnosis of PTS, the presence of typical clinical features of venous insufficiency in a patient with previous DVT provides strong supporting evidence. The most commonly used diagnostic criterion for PTS is the Villalta Scale (<LINK REF="REF-Villalta-1994" TYPE="REFERENCE">Villalta 1994</LINK>). This considers five symptoms (pain, cramps, heaviness, paraesthesias, and pruritus) and six signs (pre-tibial oedema, hyperpigmentation, venous ectasia, redness, skin irritation, and pain during calf compression) in the affected limb. Each element is scored on a scale of 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe) and the scores totaled. Total scores are then used to diagnose PTS: 0 to 4 no PTS, 5 to 9 mild PTS, 10 to 14 moderate PTS, and &gt; 14 or ulceration = severe PTS.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-03-01 03:36:23 +0000" MODIFIED_BY="Heather  Maxwell">
<P>The standard intervention for both the prevention and treatment of PTS is elastic compression stocking (ECS) therapy of the legs. Compression therapy of the legs is assumed to reduce oedema, accelerate venous blood flow, and improve venous pump function (<LINK REF="REF-Partsch-1991" TYPE="REFERENCE">Partsch 1991</LINK>). It is the treatment of first choice for PTS (<LINK REF="REF-Partsch-1991" TYPE="REFERENCE">Partsch 1991</LINK>). However, compression treatment sometimes leads to discomfort and has been associated with poor compliance, which renders oral drug treatment an attractive option. In addition, the benefits of ECS for PTS have not been fully proven, furthering the need to investigate alternative interventions.</P>
<P>Rutosides are a group of compounds derived from horse chestnut (Latin name: Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (<LINK REF="REF-Bombardelli-1996" TYPE="REFERENCE">Bombardelli 1996</LINK>). The active component of horse chestnut seed extract (HCSE) is escin (also spelled aescin) (<LINK REF="REF-Guillaume-1994" TYPE="REFERENCE">Guillaume 1994</LINK>; <LINK REF="REF-Lorenz-1960" TYPE="REFERENCE">Lorenz 1960</LINK>; <LINK REF="REF-Schrader-1995" TYPE="REFERENCE">Schrader 1995</LINK>). Rutosides and escin are known as 'venoactive' or 'phlebotonic' remedies.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-03-01 03:37:45 +0000" MODIFIED_BY="Heather  Maxwell">
<P>In chronic venous insufficiency (CVI) patients, white blood cells accumulate in the affected limbs (<LINK REF="REF-Moyses-1987" TYPE="REFERENCE">Moyses 1987</LINK>; <LINK REF="REF-Thomas-1988" TYPE="REFERENCE">Thomas 1988</LINK>) resulting in activation of enzymes which degrade the protein within the capillary walls (<LINK REF="REF-Sarin-1993" TYPE="REFERENCE">Sarin 1993</LINK>). Studies have shown that escin inhibits these enzymes thereby preventing fluid leakage and swelling due to loss of capillary wall patency (<LINK REF="REF-Facino-1995" TYPE="REFERENCE">Facino 1995</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-08-27 12:35:28 +0100" MODIFIED_BY="[Empty name]">
<P>There is evidence to support the use of rutosides for rapid relief of signs or symptoms in CVI and microangiopathy (<LINK REF="REF-Cesarone-2005" TYPE="REFERENCE">Cesarone 2005</LINK>). A Cochrane review of 17 trials comparing HCSE against placebo, ECS, or other medications concluded that HCSE is effective for short-term treatment of CVI symptoms such as leg pain and oedema, and that adverse events were mild and infrequent (<LINK REF="REF-Pittler-2012" TYPE="REFERENCE">Pittler 2012</LINK>). However, it is not known whether rutosides are effective and safe in the treatment of post-thrombotic syndrome.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-07-03 09:48:15 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness (improvement or deterioration in symptoms) and safety of rutosides for treatment of post-thrombotic syndrome (PTS) in patients with DVT compared to placebo, no intervention, elastic compression stockings (ECS), or any other treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-15 13:23:33 +0100" MODIFIED_BY="Cathryn  Broderick">
<SELECTION_CRITERIA MODIFIED="2015-09-15 13:23:33 +0100" MODIFIED_BY="Cathryn  Broderick">
<CRIT_STUDIES MODIFIED="2015-09-15 13:23:33 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) evaluating rutosides in the treatment of PTS. Trials which use allocation processes that are transparent before assignment, such as open list of random numbers, case record, day of the week, surname, and so forth, are classified as CCTs.</P>
<P>This review evaluated rutosides in the treatment of PTS. The effects of rutosides on prevention of PTS are reported in the Cochrane review by <LINK REF="REF-Morling-2015" TYPE="REFERENCE">Morling 2015</LINK>.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-03-01 03:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>Men and women of any age with complaints or clinical changes of the legs after a previous DVT, with PTS diagnosed by a recognised scoring system. Methods considered acceptable for diagnosis of DVT were ultrasound, venography, and impedance plethysmography.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-03-01 03:45:12 +0000" MODIFIED_BY="[Empty name]">
<P>The primary intervention was rutosides (any formulation at any dose). Comparisons were with placebo or no intervention, ECS, and any other treatment (including an alternative type or dosage of rutosides and other venoactive remedies). Other kinds of concomitant treatment (including ECS) were equal in both groups, and they were not the comparator treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-09-15 11:56:08 +0100" MODIFIED_BY="Cathryn  Broderick">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-09-15 11:56:08 +0100" MODIFIED_BY="Cathryn  Broderick">
<UL>
<LI>Occurrence of leg ulceration over time (yes or no)</LI>
<LI>Any improvement of PTS (yes or no)</LI>
<LI>Any deterioration of PTS (yes or no)</LI>
<LI>The definitions used in each trial paper for PTS were accepted provided they included a systematic clinical history and scoring of physical examinations. Some trials may report only changes in complaints over time. These are less valid indicators of effectiveness as the complaints may vary</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-09-09 10:15:17 +0100" MODIFIED_BY="Cathryn  Broderick">
<UL>
<LI>Any reduction of oedema in PTS (yes or no)</LI>
<LI>Any reduction of pain in PTS (yes or no)</LI>
<LI>Any recurrence of DVT or pulmonary embolism (yes or no)</LI>
<LI>Compliance</LI>
<LI>Adverse effects after initiation of rutosides</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-09-09 10:15:38 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>There was no restriction on language of publication or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-09-09 10:15:38 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>For this update the Cochrane Vascular Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched September 2015) and the Cochrane Register of Studies (CRS) (<A HREF="http://www.metaxis.com/CRSWeb/Index.asp">http://www.metaxis.com/CRSWeb/Index.asp</A>) ((CENTRAL) 2015, Issue 8). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search the CRS. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, and AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Vascular Group module in the <I>Cochrane Library</I> (<A HREF="http://www.cochranelibrary.com">www.cochranelibrary.com</A>).</P>
<P>The following trial databases were searched (September 2015) by the TSC for details of ongoing and unpublished studies using the terms post-thrombotic or postthrombotic:</P>
<UL>
<LI>World Health Organization International Clinical Trials Registry Platform (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>);</LI>
<LI>ISRCTN register (<A HREF="http://www.isrctn.com/">http://www.isrctn.com/</A>)</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-07-17 08:25:49 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Reference lists of identified studies were scrutinised in order to identify further citations.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-15 11:57:32 +0100" MODIFIED_BY="Cathryn  Broderick">
<STUDY_SELECTION MODIFIED="2015-09-08 13:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (JM and DNK) independently assessed studies for inclusion. JM and SEY independently extracted information from the trials. Disagreement was resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-03-01 03:54:45 +0000" MODIFIED_BY="Marlene Stewart">
<P>Details of the studies were extracted and summarised using a data extraction sheet.</P>
<P>The following data items were collected, where available.<BR/>
</P>
<UL>
<LI>Trial setting (country, and whether primary or secondary care).</LI>
<LI>Method of randomisation.</LI>
<LI>PTS diagnosis assessment method, and whether blinded.</LI>
<LI>Length of follow-up.</LI>
<LI>Number of patients randomised.</LI>
<LI>Inclusion criteria.</LI>
<LI>Exclusion criteria.</LI>
<LI>Description of interventions and co-interventions.</LI>
<LI>Baseline characteristics of groups for important variables (e.g. first DVT, recurrent DVT).</LI>
<LI>Definition of PTS.</LI>
<LI>Results.</LI>
<LI>Compliance.</LI>
<LI>Adverse events.</LI>
<LI>Intention-to-treat analysis.</LI>
<LI>Number and reasons for withdrawals.</LI>
<LI>Source of funding.</LI>
<LI>Use of an a priori sample size or power calculation.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-08 13:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (JM and SEY) independently assessed bias using the Cochrane risk of bias tool. Disagreement was resolved by discussion. Five key domains were examined for bias: selection bias; performance bias; attrition bias; detection bias; and reporting bias. These were assessed and classified as either at a low risk of bias or a high risk of bias. Where insufficient detail was reported in a study to assess the risk, this was reported as 'unclear'. In addition, any other form of bias noted in the study was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-03-01 03:59:46 +0000" MODIFIED_BY="[Empty name]">
<P>For dichotomous variables the odds ratio (OR) was reported. All of the outcomes for this review were considered as dichotomous (present or absent).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-07-04 13:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>For all outcomes the unit of analysis was the number of patients.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-09-15 11:57:32 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Where outcome variables were not reported the available data were analysed. For missing data related to losses to follow-up the data were assumed to be missing at random. The potential impact of missing data was considered by the review authors when making their final conclusions. It was not necessary for the review authors to contact the original investigators to request missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-03-01 04:01:29 +0000" MODIFIED_BY="Marlene Stewart">
<P>We planned to explore heterogeneity by examining factors that may be influential, such as the definition of PTS used by the trialists, care setting, time of follow-up, and incidence of recurrent DVT. In the absence of clinical heterogeneity we intended to test for statistical heterogeneity using the Chi<SUP>2</SUP> test.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-07-17 11:38:51 +0100" MODIFIED_BY="[Empty name]">
<P>Funnel plots were planned to consider reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-09-15 11:57:24 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Mantel-Haenzel fixed-effect model analyses were planned. Cross-over trials were analysed examining the first treatment period only.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-03-01 04:01:57 +0000" MODIFIED_BY="[Empty name]">
<P>Where sufficient numbers of studies were identified, subgroup analyses were undertaken for the differing comparator groups (versus placebo or no treatment, versus ECS, and versus alternative venoactive remedies).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-09 10:21:07 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>If applicable, RCTs and CCTs were analysed separately to access the efficacy of the effect estimation, calculated with the Mantel-Haenszel test. Where sufficient trials were available we reanalysed the data excluding low quality trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings</HEADING>
<P>A table compiling and summarising the best evidence of relevant outcomes was constructed for comparisons of rutosides with the three comparator groups i) placebo or no comparator, ii) ECS and iii) hidrosmina). Study populations consisting of patients with PTS were considered. The most important and clinically relevant outcomes (both desirable and undesirable) that were thought to be essential for decision-making were occurrence of leg ulceration over time, any improvement of PTS and any deterioration of PTS. None of the included studies reported on leg ulceration and so for this update only any improvement of PTS and any deterioration of PTS were selected for the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> and <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>. Assumed control intervention risks were calculated by the mean number of events in the control groups of the selected studies for each outcome. The system developed by the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE working group) was used for grading the quality of evidence as high, moderate, low and very low, based on within-study risk of bias, directness of evidence, heterogeneity, precision of effects estimates, and risk of population bias (<A HREF="https://archie.cochrane.org/sections/documents/view?document=944999093011303392&amp;format=REVMAN#REF-GRADE-2004">GRADE 2004</A>).</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-15 11:59:52 +0100" MODIFIED_BY="Cathryn  Broderick">
<STUDY_DESCRIPTION MODIFIED="2015-09-08 13:23:27 +0100" MODIFIED_BY="[Empty name]">
<P> </P>
<SEARCH_RESULTS MODIFIED="2015-09-08 13:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. No additional studies were identified for this update.</P>
<P>Following consideration of the inclusion and exclusion criteria, three studies (four reports) were suitable for inclusion with six studies excluded. Briefly, these were two RCTs and an open cross-over study. The included studies allowed three comparisons to be examined: rutosides versus placebo or no treatment (<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989;</LINK> <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>), rutosides versus ECS (<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>), and rutosides versus an alternative venoactive remedy (<LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK>). See <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> and <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK> for further details of each study.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-03-01 04:15:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK>
</P>
<P>This was a multi-centre, double blind, RCT to assess the use of 0-(&#946;-hydroxyethyl)-rutosides (1200 mg/day) in 84 patients with unilateral PTS of at least six months duration and a venography proven DVT in the affected leg. Consenting ambulant outpatients (referred by their general practitioner (GP)) were randomised by a computer system to receive either rutosides or placebo for eight weeks. There were 48 male and 35 female participants (mean age 53 to 54 years). Each patient was followed up at four weeks and eight weeks. At each visit a standard questionnaire recorded tiredness, pain, heaviness, feeling of swelling, restless legs, cramps, presence of pitting oedema on a scale of: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. In addition, minimum ankle circumferences were recorded as well as both the patients' and the (blinded) doctors' opinion of the efficacy of the treatment.</P>
<P>This study provided data for the comparison: rutosides versus placebo or no treatment.</P>
<P>
<LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK>
</P>
<P>This was an open cross-over study of 0-(&#946;-hydroxyethyl)-rutosides (900 mg/day) versus hidrosmina (600 mg/day), each for six months. Hidrosmina is an alternative venoactive remedy. Twenty-nine outpatients with unilateral PTS of at least 12 months duration following a venography proven lower limb DVT were randomised. The Kakkar and Lawrence scoring system was used to record the severity of symptoms and signs. The initial drug was taken for six months. The drug was then discontinued and the alternative taken for a further six months. Following discontinuation of both drugs, patients were examined at three and six months. For this review only the first treatment period was considered.</P>
<P>This study provided data for the comparison: rutosides versus hidrosmina (an alternative venoactive remedy).</P>
<P>
<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>
</P>
<P>This was a randomised controlled pilot study comparing the efficacy of elastic compression stockings (ECS), hydroxyethylrutosides (HR) (2000 mg/day), or both in the treatment of PTS in ultrasound proven lower limb DVT. A total of 120 consecutive patients were randomised by a computer system, with 40 patients in each of the three groups. They received treatment for 12 months. In order to assess the efficacy of HR, this Cochrane review compared the use of HR and ECS with elastic compression stockings alone. There were 36 male and 84 female participants (aged 24 to 91 years). Each patient was followed up at three months, six months, and 12 months. At each visit an investigator blind to the participant's treatment scored the presence and severity of PTS according to the Villalta scale. Those whose scores fell to below five or that had a 30% reduction were considered to have a PTS improvement, those that had an increase by at least 30% were considered to have a PTS deterioration. Compliance with treatment was also recorded.</P>
<P>This study provided data for the comparisons: rutosides versus placebo or no treatment, and rutosides versus ECS.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-01 04:16:24 +0000" MODIFIED_BY="[Empty name]">
<P>Following application of the inclusion and exclusion criteria, six studies were excluded. Four of the studies investigated the effect of rutosides on the treatment of deep venous insufficiency with a mixed causality, not PTS (<LINK REF="STD-Cospite-1986" TYPE="STUDY">Cospite 1986</LINK>; <LINK REF="STD-Diebschlag-1994" TYPE="STUDY">Diebschlag 1994</LINK>; <LINK REF="STD-Incandela-2002" TYPE="STUDY">Incandela 2002</LINK>; <LINK REF="STD-Rose-1970" TYPE="STUDY">Rose 1970</LINK>). Two studies either presented no results or it was not possible to extract the results related to PTS (<LINK REF="STD-De-Jongste-1986" TYPE="STUDY">De Jongste 1986</LINK>; <LINK REF="STD-Nill-1970" TYPE="STUDY">Nill 1970</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-03-01 04:25:42 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for a summary of the risk of bias assessment.</P>
<ALLOCATION MODIFIED="2012-07-17 11:44:13 +0100" MODIFIED_BY="[Empty name]">
<P>All three studies used random assignment of participants to each of the study groups. Both <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> and <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> specified computer randomisation schedules. <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> did not specify the randomisation schedule. </P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-01 04:25:42 +0000" MODIFIED_BY="[Empty name]">
<P>The three studies included in this review all used slightly different trial methodologies, making the blinding process slightly different for each. De Jongste's traditional RCT (intervention versus placebo) stated double blinding, suggesting that both participants and study personnel were unaware of which treatment the individual was receiving (<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK>).</P>
<P>
<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> had three trial arms. Participants were not blinded as patients received either elastic stockings, oral HR treatment, or both and it is difficult to use a placebo for the patients in the non-elastic stockings groups although sham devices are available. Some of the measured outcomes in this study were mostly based on severity of clinical symptoms, which could potentially be influenced by patients&#8217; perspectives. Other measured outcomes were based on clinical signs, which are unlikely to be influenced by patients&#8217; perspectives. There was no placebo in the ECS alone group so participants would be aware of whether they were receiving the trial medication. Study personnel recording outcome data were unaware of the treatment allocation and the results of previous measurements.</P>
<P>In the <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> open cross-over trial it was not stated if patients were blinded to the treatment allocation. In addition, some of the measured outcomes in this study were based on the subjective severity of clinical symptoms and might potentially be influenced by patients' perspectives. All patients were examined by the same physician to increase the standardisation of measurement. It was not stated if the study personnel were blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-01-24 09:48:12 +0000" MODIFIED_BY="Marlene Stewart">
<P>All excluded patients were accounted for and satisfactory reasons for exclusion given in all three included studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-01-24 09:47:41 +0000" MODIFIED_BY="Marlene Stewart">
<P>In all included studies the pre-specified outcomes of interest in this review were reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-03-01 04:25:10 +0000" MODIFIED_BY="Marlene Stewart">
<P>There were no additional significant bias concerns.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-15 11:59:52 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Key effects of the intervention are shown in the data analysis table below. For each of the studies the final time point outcome was reported. It should be noted that the duration of each study differed. The results reported from the three studies allowed three comparisons to be made.</P>
<P>1. Rutosides versus placebo or no treatment.</P>
<P>2. Rutosides versus ECS.</P>
<P>3. Rutosides versus hidrosmina (an alternative venoactive remedy).</P>
<SUBSECTION>
<HEADING LEVEL="3">Occurrence of leg ulceration over time</HEADING>
<P>None of the studies reported on the development of ulceration. <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> noted a statistically non-significant increase in ulcer healing in the rutoside group (2/15) compared with hidrosmina (1/14) (P = 0.59).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Improvement of PTS</HEADING>
<P>Different reporting methods were used by each study. Whilst not measured in identical ways these were comparable.</P>
<P>
<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> shows a combined OR of 1.29 (95% CI 0.69 to 2.41, P = 0.42) for rutosides versus placebo or no treatment (<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK>; <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>) (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). This was supplemented by <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> reporting on the improvement of each component of PTS: tiredness (rutosides 46%, placebo 26%); heaviness (rutosides 41%, placebo 29%); restless legs (rutosides 17%, placebo 14%); and cramps (rutosides 34%, placebo 36%).</P>
<P>For rutosides versus ECS, <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> found a marginal statistically non-significant lower proportion of patients improving in the rutoside treated group (rutosides improvement 26/40, ECS improvement 28/40, P = 0.63) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>For rutosides versus hidrosmina, <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> found statistically significantly more patients with improvement of PTS in the hidrosmina treated group (hidrosmina improvement 9/15, rutoside improvement 3/14, P = 0.04) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deterioration of PTS</HEADING>
<P>Different reporting methods were used by each study. Whilst not measured in identical ways these were comparable.</P>
<P>
<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) found higher rates of PTS deterioration in the rutoside group compared with the placebo or no treatment group but this was not statistically significant (rutosides deterioration 9/40, placebo or no treatment deterioration 6/40, P = 0.39).</P>
<P>In <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>, for rutosides versus ECS there was more deterioration in the rutoside group (rutoside deterioration 9/40, ECS deterioration 6/40, P = 0.39) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) but this was not statistically significant.</P>
<P>For rutosides versus hidrosmina, <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> reported deterioration of PTS in 0/14 patients in the rutoside group and deterioration in 2/15 patients in the hidrosmina group (P = 0.29) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reduction of oedema or swelling</HEADING>
<P>Only <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> reported on improvement in swelling, with the rutosides group showing more improvement than the placebo or no treatment group (20/41 versus 18/42) but this was not statistically significant (P = 0.59) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>
<LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> reported mean ankle and calf circumferences at six, 12, and 18 month intervals. During treatment with both rutosides and hidrosmina <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> reported a gradual reduction in mean values, however this was not sustained following withdrawal of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reduction of pain</HEADING>
<P>
<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> was the only study to report reduction in pain, with slightly higher rates of pain reduction in the rutosides group than the placebo or no treatment group (16/41 versus 14/42) but this was not statistically significant (P = 0.59) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Recurrence of DVT or pulmonary embolism</HEADING>
<P>
<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> was the only study to report reoccurrence of DVT or pulmonary embolism (PE). This event occurred once in each of the rutosides, ECS, and placebo or no intervention groups (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Compliance</HEADING>
<P>
<LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> was the only study to report on compliance, with 70/80 wearing stockings for &#8805; 80% of the study and 64/80 taking &#8805; 80% of the study medication. Note the numbers included all three groups (rutosides versus ECS versus rutosides plus ECS) as it was not possible to separate them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects after initiation of rutosides</HEADING>
<P>
<LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> reported 'mild side effects' in 7/41 of the rutoside group and 5/42 of the placebo or no intervention group (P = 0.51) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). As above, <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> did not separate the outcomes fully with 2/80 not tolerating ECS and 6/80 stopping the medication due to side effects, described as mainly gastrointestinal. <LINK REF="STD-Monreal-1994" TYPE="STUDY">Monreal 1994</LINK> did not comment on side effects.</P>
<P>Because of the limited number of included studies we were unable to undertake heterogeneity, subgroup, reporting bias, and sensitivity analyses.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-15 12:00:18 +0100" MODIFIED_BY="Cathryn  Broderick">
<SUMMARY_OF_RESULTS MODIFIED="2013-03-01 05:47:29 +0000" MODIFIED_BY="Marlene Stewart">
<P>Participants had 29% higher odds of improvement in PTS if they received rutosides compared to placebo or no intervention based on two studies. Rates of deterioration in PTS were also higher in the group receiving rutosides versus placebo or no treatment but lower than in those receiving an alternative venoactive remedy. However, none of the results were statistically significant.</P>
<P>When compared with ECS, participants had lower odds of improvement and higher odds of deterioration of PTS in the rutoside group (again not statistically significant).</P>
<P>When two different venoactive remedies were compared, PTS improvement was more pronounced in the hidrosmina treated group compared to rutoside treatment, however this group also had higher rates of PTS deterioration (not statistically significant).</P>
<P>There was little reported on compliance and adverse effects, with slightly higher rates of mild adverse effects in the rutoside group compared with placebo or no treatment, reported by a single study, with no reports for the other comparisons.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-03-01 22:39:18 +0000" MODIFIED_BY="Marlene Stewart">
<P>This review considered DVT at any site without separate analysis of upper and lower limbs. A separate analysis would have been limited in this review given the inclusion of only three studies but should be considered for future updates.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-09-15 12:00:18 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Overall, all of the evidence presented was considered to be of low or very low quality using GRADE. This was predominantly due to the lack of both participant and researcher blinding in the included studies. With further downgrading due to this risk of bias and possible publication bias. The quality of the evidence was further limited by the small number of studies contributing to this review. The data were generated using a subjective scoring system for PTS, however this is unavoidable. The alternative would be repeated invasive pressure measures, which would be unacceptable to participants and potentially less useful than clinical symptom outcomes. Scoring systems differed across the studies but were all similar. Another notable difference in the included studies was the varied dosage of rutosides used (900 to 2000 mg/day).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-09-02 10:16:41 +0100" MODIFIED_BY="Karen Welch">
<P>The Cochrane Vascular Group Specialised Register is a comprehensive and weekly updated register of all publications relating to peripheral vascular diseases. As a result, when searched in combination with the CRS we believe that all trials with the potential for inclusion have been accessed. The search strategy was developed in conjunction with experts in the field to maximise study identification. It was not possible to contact any PTS specialists to recover any additional unpublished or ongoing studies. We remain confident in our study identification. Data collection and analysis methods were robust.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-03-01 22:44:27 +0000" MODIFIED_BY="Marlene Stewart">
<P>Six studies were excluded following the searches and of these only one referred to PTS. This double blind randomised placebo controlled study (<LINK REF="STD-De-Jongste-1986" TYPE="STUDY">De Jongste 1986</LINK>) reported its data in a way which made it impossible to extract for inclusion in this review. However, in summary, a greater reduction in oedema and greater patient reported improvement of symptoms were noted in the rutoside treated group. This is in keeping with the findings of this Cochrane review. It was not possible to identify any additional studies to assess agreement or disagreement with.</P>
<P>Our study agrees with the findings of a recent meta-analysis by <LINK REF="REF-Cohen-2012" TYPE="REFERENCE">Cohen 2012</LINK> for the outcomes we included. In addition, <LINK REF="REF-Cohen-2012" TYPE="REFERENCE">Cohen 2012</LINK> chose to analyse the risk of adverse effects, combining <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> and <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK>, and found a non-significant increased risk (RR 2.04, 95% CI 0.76 to 5.51). <LINK REF="REF-Cohen-2012" TYPE="REFERENCE">Cohen 2012</LINK> did not identify any studies additional to those we identified that compared the effects of rutosides versus placebo, no intervention, ECS, or any other treatment.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-03-01 05:59:33 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-03-01 05:57:06 +0000" MODIFIED_BY="[Empty name]">
<P>There was no evidence that rutosides were superior to the use of placebo or ECS. Overall, currently there is limited evidence that 'venoactive' or 'phlebotonic' remedies such as rutosides reduce symptoms of post-thrombotic syndrome (PTS). Mild side effects were noted in one study. The three studies included in this review provide no evidence for the use of rutosides in the treatment of PTS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-01 05:59:33 +0000" MODIFIED_BY="[Empty name]">
<P>Numerous in vitro studies conclude that rutosides reduce microvascular permeability both in healthy vessels and vessels showing signs of inflammation hence decreasing capillary flux or filtration, leakage, and swelling, with a potential improvement in signs and symptoms of PTS. Since PTS is not only dependent on platelets but also coagulation, fibrinolysis, and flow, studies have also shown that rutosides inhibit the aggregation of human red cells and platelets in vitro. Despite these in vitro research findings the effects have yet to be fully translated into human clinical trials. Also, not all studies have yet adopted the standardised Villalta Scale for the diagnosis and monitoring of PTS symptoms (<LINK REF="REF-Kahn-2009" TYPE="REFERENCE">Kahn 2009</LINK>), which is essential in future work. Larger, longer duration RCTs are required to confirm the effectiveness of rutosides for treating PTS and also to examine their long-term benefits and any benefits over the current standard therapy of ECS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-08 13:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>The review authors would like to thank Dr Martin Prins for his work on the study protocol.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-09-15 13:31:21 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Joanne Morling: declared that she is currently funded by a Diabetes UK Clinical Research Training Fellowship covering research costs and salary and is not related to this review<BR/>Su Ern Yeoh: none known<BR/>Dinanda Kolbach: none known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-15 13:31:24 +0100" MODIFIED_BY="Cathryn  Broderick">
<P>Joanne Morling: selected trials, developed data extraction tool, extracted data, assessed risk of bias, undertook analyses, wrote the review<BR/>Su Ern Yeoh: extracted data, assessed risk of bias, wrote the review<BR/>Dinanda Kolbach: wrote the protocol, checked the review</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-03-01 06:01:15 +0000" MODIFIED_BY="[Empty name]">
<P>According to Cochrane guidelines the quality of the trials was assessed using the Cochrane risk of bias tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The original protocol listed only negative primary outcomes regarding PTS. In order to present a balanced view we added a third primary outcome: 'any improvement in PTS (yes or no)'.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-09-15 13:25:15 +0100" MODIFIED_BY="Cathryn  Broderick">
<STUDIES MODIFIED="2013-03-01 06:13:58 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-03-01 06:12:17 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jongste-1989" MODIFIED="2013-03-01 06:12:17 +0000" MODIFIED_BY="[Empty name]" NAME="De Jongste 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-02-01 11:44:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jongste AB, Jonker JJ, Huisman MV, Ten Cate JW, Azar AJ</AU>
<TI>A double blind three center clinical trial on the short-term efficacy of 0-(beta-hydroxyethyl)-rutosides in patients with post-thrombotic syndrome</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1989</YR>
<VL>62</VL>
<NO>3</NO>
<PG>826-9</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:16:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-01 06:12:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jongste AB, Jonker JJC, Huisman MV, Ten Cate JW, Azar AJ</AU>
<TI>A double-blind trial on the short-term efficacy of HR in patients with the post-thrombotic syndrome</TI>
<SO>Phlebology</SO>
<YR>1990</YR>
<VL>5 Suppl 1</VL>
<PG>21-2</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monreal-1994" MODIFIED="2012-01-27 15:17:16 +0000" MODIFIED_BY="[Empty name]" NAME="Monreal 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-27 15:17:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monreal M, Callejas JM, Martorell A, Lisbona C, Lerma R</AU>
<TI>A prospective study of the long-term efficacy of two different venoactive drugs in patients with post-thrombotic syndrome</TI>
<SO>Phlebology</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>37-40</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-2005" MODIFIED="2013-02-01 11:44:56 +0000" MODIFIED_BY="[Empty name]" NAME="Prandoni 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-02-01 11:44:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P</AU>
<TI>Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2005</YR>
<VL>93</VL>
<NO>1</NO>
<PG>183-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-01 06:13:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cospite-1986" MODIFIED="2013-02-08 10:50:36 +0000" MODIFIED_BY="[Empty name]" NAME="Cospite 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-02-08 10:50:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cospite M, Amato C, Milio G, Scrivano V</AU>
<TI>Changes of venous haemodynamics in subjects with post-thrombotic syndrome, treated with high doses of diosmine in association with other bioflavonoids</TI>
<SO>What is New in Angiology? Trends and Controversies</SO>
<YR>1986</YR>
<ED>Maurer PC, Becker HM, Heidrich H, Hoffmann G, Kriessmann A, Muller-Wiefel H, Pratorius C</ED>
<PB>Zuckschwerdt W</PB>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jongste-1986" MODIFIED="2013-02-01 11:45:12 +0000" MODIFIED_BY="[Empty name]" NAME="De Jongste 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-02-01 11:45:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>De Jongste AB, Ten Cate JW, Huisman MV</AU>
<TI>The effectiveness of 0-(beta-hydroxyethyl)-rutosides (HR) in the post-thrombotic syndrome (PTS)</TI>
<SO>Phlebology'85</SO>
<YR>1986</YR>
<PG>837-9</PG>
<EN>Supplement No 285</EN>
<ED>Negus D, Jantet G</ED>
<PB>John Libbey and Co. Ltd</PB>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diebschlag-1994" MODIFIED="2013-02-01 11:45:28 +0000" MODIFIED_BY="[Empty name]" NAME="Diebschlag 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-02-01 11:45:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diebschlag W, Nocker W, Lehmacher W, Rehn D</AU>
<TI>A clinical comparison of two doses of 0-(beta-Hydroxyethyl)-rutosides (oxerutins) in patients with chronic venous insufficiency</TI>
<SO>Journal of Pharmaceutical Medicine</SO>
<YR>1994</YR>
<VL>4</VL>
<NO>1</NO>
<PG>7-14</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Incandela-2002" MODIFIED="2013-03-01 06:13:32 +0000" MODIFIED_BY="[Empty name]" NAME="Incandela 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-03-01 06:13:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Incandela L, Belcaro G, Renton S, DeSanctis MT, Cesarone MR, Bavera, et al</AU>
<TI>HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial</TI>
<SO>Journal of Cardiovascular Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>7 Suppl 1</VL>
<PG>S7-10</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nill-1970" MODIFIED="2013-03-01 06:13:58 +0000" MODIFIED_BY="[Empty name]" NAME="Nill 1970" YEAR="1970">
<REFERENCE MODIFIED="2013-03-01 06:13:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nill HJ, Fischer H</AU>
<TI>Comparative investigations concerning the effect of extract of horse chestnut upon the pressure-volume-diagram of patients with venous disorders</TI>
<TO>Vergleichende Untersuchungen zur Beeinflussung des Druck-Volumen-Diagramms durch Roßkastanienextrakt bei Venenkranken</TO>
<SO>Arztliche Forschung</SO>
<YR>1970</YR>
<VL>24</VL>
<NO>5</NO>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rose-1970" MODIFIED="2012-01-27 15:17:53 +0000" MODIFIED_BY="[Empty name]" NAME="Rose 1970" YEAR="1970">
<REFERENCE MODIFIED="2012-01-27 15:17:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rose SS</AU>
<TI>A report on the use of an hydroxyethylrutoside in symptoms due to venous back pressure and allied conditions in the lower limbs</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1970</YR>
<VL>24</VL>
<NO>4</NO>
<PG>161-4</PG>
<IDENTIFIERS MODIFIED="2012-01-27 15:17:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-05-13 13:43:46 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-09-15 13:25:15 +0100" MODIFIED_BY="Cathryn  Broderick">
<ADDITIONAL_REFERENCES MODIFIED="2015-09-15 13:23:52 +0100" MODIFIED_BY="Cathryn  Broderick">
<REFERENCE ID="REF-Bombardelli-1996" NAME="Bombardelli 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bombardelli E, Morazzoni P, Griffini A</AU>
<TI>Aesculus hippocastanum L</TI>
<SO>Fitoterapia</SO>
<YR>1996</YR>
<VL>67</VL>
<NO>6</NO>
<PG>483-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cesarone-2005" MODIFIED="2012-01-31 13:08:03 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Cesarone 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, et al</AU>
<TI>HR, 0-(beta-hydroxyethyl)-rutosides; (Venoruton): rapid relief of signs/symptoms in chronic venous insufficiency and microangiopathy: a prospective, controlled study</TI>
<SO>Angiology</SO>
<YR>2005</YR>
<VL>56</VL>
<NO>2</NO>
<PG>165-72</PG>
<IDENTIFIERS MODIFIED="2008-11-03 14:41:40 +0000" MODIFIED_BY="Heather  Maxwell"/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2012" MODIFIED="2013-02-01 11:46:12 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 2012" TYPE="JOURNAL_ARTICLE">
<AU>Cohen JM, Akl EA, Kahn SR</AU>
<TI>Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials</TI>
<SO>Chest</SO>
<YR>2012</YR>
<VL>141</VL>
<NO>2</NO>
<PG>308-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Facino-1995" MODIFIED="2008-11-03 14:41:46 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Facino 1995" TYPE="JOURNAL_ARTICLE">
<AU>Facino RM, Carini M, Stefani R, Aldini G, Saibene L</AU>
<TI>Anti-elastase and anti-hyaluronidase activities of saponins and sapogenins from Hedera helix, Aesculus hippocastanum, and Ruscus aculeatus: factors contributing to their efficacy in the treatment of venous insufficiency</TI>
<SO>Archiv der Pharmazie</SO>
<YR>1995</YR>
<VL>328</VL>
<NO>10</NO>
<PG>720-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guillaume-1994" MODIFIED="2008-11-03 14:41:50 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Guillaume 1994" TYPE="JOURNAL_ARTICLE">
<AU>Guillaume M, Padioleau F</AU>
<TI>Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>1</NO>
<PG>25-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-01-27 15:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available at www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-2009" MODIFIED="2012-04-10 11:43:21 +0100" MODIFIED_BY="[Empty name]" NAME="Kahn 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C; Subcommittee on control of anticoagulation of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis</AU>
<TI>Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>5</NO>
<PG>879-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorenz-1960" MODIFIED="2012-02-01 10:41:46 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Lorenz 1960" TYPE="JOURNAL_ARTICLE">
<AU>Lorenz D, Marek ML</AU>
<TI>Das therapeutische wirksame Prinzip der Rosskastanie (Aesculus hippocastanum)</TI>
<SO>Arzneimittel-Forschung/Drug Research</SO>
<YR>1960</YR>
<VL>10</VL>
<PG>263-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morling-2015" MODIFIED="2015-09-15 13:23:52 +0100" MODIFIED_BY="Cathryn  Broderick" NAME="Morling 2015" TYPE="COCHRANE_REVIEW">
<AU>Morling JR, Yeo SE, Kolbach DN</AU>
<TI>Rutosides for the prevention of post-thrombotic syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-09-15 13:23:52 +0100" MODIFIED_BY="Cathryn  Broderick">
<IDENTIFIER MODIFIED="2015-09-15 13:23:50 +0100" MODIFIED_BY="Cathryn  Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD005626.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moyses-1987" MODIFIED="2012-10-09 10:30:25 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Moyses 1987" TYPE="JOURNAL_ARTICLE">
<AU>Moyses C, Cederholm-Williams SA, Michel CC</AU>
<TI>Haemoconcentration and accumulation of white cells in the feet during venous stasis</TI>
<SO>International Journal of Microcirculation: Clinical and Experimental</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>4</NO>
<PG>311-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Partsch-1991" MODIFIED="2012-10-09 10:30:17 +0100" MODIFIED_BY="[Empty name]" NAME="Partsch 1991" TYPE="JOURNAL_ARTICLE">
<AU>Partsch H</AU>
<TI>Compression therapy of the legs. A review</TI>
<SO>Journal of Dermatologic Surgery and Oncology</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>10</NO>
<PG>799-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2012" MODIFIED="2015-08-27 12:35:28 +0100" MODIFIED_BY="[Empty name]" NAME="Pittler 2012" TYPE="COCHRANE_REVIEW">
<AU>Pittler MH, Ernst E</AU>
<TI>Horse chestnut seed extract for chronic venous insufficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2013-02-01 11:48:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-02-01 11:48:58 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003230.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prandoni-1996" NAME="Prandoni 1996" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al</AU>
<TI>The long-term clinical course of acute deep venous thrombosis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sarin-1993" MODIFIED="2008-11-03 14:42:05 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Sarin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sarin S, Andaz A, Shields DA, Scurr JH, Coleridge Smith PD</AU>
<TI>Neutrophil activation in venous disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>444</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schrader-1995" MODIFIED="2008-11-03 14:42:11 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Schrader 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schrader E, Schwankl W, Sieder C, Christoffel V</AU>
<TI>Comparison of the bioavailability of beta-aescin after single oral administration of two different drug formulations containing an extract of horse-chestnut seeds</TI>
<TO>Vergleichende Untersuchung zur Bioverfügbarkeit von ß-Aescin nach oraler Einmalverabreichung zweier Rosskastaniensamenextrakt enthaltender, galenisch unterschiedlicher Darreichungsformen</TO>
<SO>Pharmazie</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>9</NO>
<PG>623-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1988" MODIFIED="2012-02-01 10:54:01 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Thomas 1988" TYPE="JOURNAL_ARTICLE">
<AU>Thomas PR, Nash GB, Dormandy JA</AU>
<TI>White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin</TI>
<SO>BMJ</SO>
<YR>1988</YR>
<VL>296</VL>
<NO>6638</NO>
<PG>1693-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villalta-1994" MODIFIED="2012-07-16 10:17:20 +0100" MODIFIED_BY="[Empty name]" NAME="Villalta 1994" TYPE="JOURNAL_ARTICLE">
<AU>Villalta S, Bagatella P, Piccioli A, Lensing A, Prins M, Prandoni P</AU>
<TI>Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome</TI>
<SO>Haemostasis</SO>
<YR>1994</YR>
<VL>24</VL>
<PG>158a</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-09-15 13:25:15 +0100" MODIFIED_BY="Cathryn  Broderick">
<REFERENCE ID="REF-Kolbach-2006" MODIFIED="2015-09-08 13:26:41 +0100" MODIFIED_BY="[Empty name]" NAME="Kolbach 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Kolbach DN, Prins MH</AU>
<TI>Rutosides for treatment of post-thrombotic syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-08-27 12:34:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-08-27 12:34:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005625"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morling-2013" MODIFIED="2015-09-15 13:25:15 +0100" MODIFIED_BY="Cathryn  Broderick" NAME="Morling 2013" TYPE="COCHRANE_REVIEW">
<AU>Morling JR, Yeoh SE, Kolbach DN</AU>
<TI>Rutosides for treatment of post-thrombotic syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-09-15 13:24:33 +0100" MODIFIED_BY="Cathryn  Broderick">
<IDENTIFIER MODIFIED="2015-09-15 13:24:23 +0100" MODIFIED_BY="Cathryn  Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD005625.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-11-07 14:42:38 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-03-04 10:07:26 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-03-04 10:07:26 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-03-01 06:07:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Jongste-1989">
<CHAR_METHODS MODIFIED="2013-03-01 06:06:56 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double blind, placebo controlled trial</P>
<P>Treatment period: eight weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-01 06:07:34 +0000" MODIFIED_BY="[Empty name]">
<P>Conducted in outpatient department of three Dutch hospitals</P>
<P>Total number randomised: 84 (males 48, female 36)</P>
<P>Mean age: intervention 53 (SD 12), placebo 54 (SD 13) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-01 06:02:42 +0000" MODIFIED_BY="[Empty name]">
<P>Arm 1: 0-(&#946;-hydroxyethyl)-rutosides 1200 mg daily (in four divided doses)</P>
<P>Arm 2: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-10 11:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>Deterioration of PTS</P>
<P>Presence of pain</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-16 14:34:16 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-01 06:05:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monreal-1994">
<CHAR_METHODS MODIFIED="2013-03-01 06:05:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, open, cross-over trial</P>
<P>Phase 1: first treatment period, six months</P>
<P>Phase 2: second treatment period, six months</P>
<P>Phase 3: washout period, four weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-01 06:05:35 +0000" MODIFIED_BY="[Empty name]">
<P>Conducted in single centre, outpatient department, Spain</P>
<P>Total number randomised 29 (males 21, female 8)</P>
<P>Mean age: 60 years (range 39 to 80)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-01 06:05:44 +0000" MODIFIED_BY="[Empty name]">
<P>Arm 1: 0-(&#946;-hydroxyethyl)-rutosides 900 mg daily (in three divided doses)</P>
<P>Arm 2: hidrosmina 600 mg daily (in three divided doses)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-10 11:46:24 +0100" MODIFIED_BY="[Empty name]">
<P>Presence of pain (Kakkar and Lawrence Scoring System)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-16 14:34:50 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-01 06:07:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prandoni-2005">
<CHAR_METHODS MODIFIED="2013-03-01 06:06:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single blind, controlled trial</P>
<P>Treament period: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-01 06:07:16 +0000" MODIFIED_BY="[Empty name]">
<P>Single centre Italian study</P>
<P>Total number randomised 120 (males 33, female 87)</P>
<P>Age range: 24 to 91 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-01 06:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Arm 1: 0-(&#946;-hydroxyethyl)-rutosides 2000 mg daily (in two divided doses)</P>
<P>Arm 2: elastic compression stockings (below knee, 30 to 40 mmHg at ankle)</P>
<P>Arm 3: 0-(&#946;-hydroxyethyl)-rutosides 2000 mg daily (in two divided doses) and elastic compression stockings (below knee, 30 to 40 mmHg at ankle)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-17 11:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Deterioration of PTS (Villalta Scale)</P>
<P>Improvement of PTS (Villalta Scale)</P>
<P>Compliance with therapy</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-16 14:34:33 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-03-01 06:11:22 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-11-07 14:43:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cospite-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 14:43:43 +0000" MODIFIED_BY="[Empty name]">
<P>Not post-thrombotic syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-01 06:11:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Jongste-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-01 06:11:22 +0000" MODIFIED_BY="[Empty name]">
<P>No results presented suitable for data extraction or consistent with review outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-07 14:43:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diebschlag-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-07 14:43:48 +0000" MODIFIED_BY="[Empty name]">
<P>Not post-thrombotic syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 17:29:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Incandela-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 17:29:57 +0000" MODIFIED_BY="[Empty name]">
<P>Not post-thrombotic syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-20 08:45:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nill-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-20 08:45:57 +0000" MODIFIED_BY="[Empty name]">
<P>Not possible to extract post-thrombotic syndrome data alone, and the outcome reported is not relevant for this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-22 17:30:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rose-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-22 17:30:51 +0000" MODIFIED_BY="[Empty name]">
<P>Not post-thrombotic syndrome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-05-13 13:43:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-03-04 10:07:26 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-01 06:09:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-14 07:59:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned ..... with the use of a computerised random assignment method".</P>
<P>Comment: The randomisation schedule was specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-14 10:52:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Quote: "patients were randomly assigned".</P>
<P>Comment: The randomisation schedule was not specified. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:09:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Quote: "consenting patients were randomly allocated ..... according to a computer generated list".</P>
<P>Comment: The randomisation schedule was specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-01 06:10:09 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:03:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Quote: "A series of coded sealed envelopes for decoding any particular case was supplied to the local hospital pharmacy".<BR/>Comment: Unlikely patients and personnel were aware of the randomisation schedule.  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:10:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Comment: Unlikely patients were aware of the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:09:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Comment: Unlikely patients were aware of the randomisation schedule.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-03-04 10:07:26 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-03-01 06:10:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Quote: "double-blind".</P>
<P>Comment: Suggesting both participants and study personnel were unaware of which treatment the individual was receiving.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-03-02 15:13:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Open cross-over pilot study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-03-04 10:07:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Participants were not blinded as patients received either elastic stockings, oral HR treatment or both and it is difficult to use a placebo for the patients in the non-elastic stockings groups although sham devices are available. Some of the measured outcomes in this study are mostly based on severity of clinical symptoms which could potentially be influenced by patients&#8217; perspectives. Other measured outcomes were based on clinical signs which are unlikely to be influenced by patients&#8217; perspectives.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-03-01 06:10:31 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-03-01 06:10:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Quote: "double-blind", "All the assessments were performed by the same investigators at each center..."</P>
<P>Comment: Not reported if investigators were aware of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-03-02 15:13:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Open cross-over pilot study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-02-16 15:00:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Assessment was carried out by an investigator who was aware as to the side of the index DVT but was unaware of the treatment allocation and the results of previous measurements.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-02-16 15:01:48 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-03-01 06:10:35 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-01 06:10:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Comment: All excluded patients were accounted for and satisfactory reasons for exclusion given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-01 06:10:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Comment: All excluded patients were accounted for and satisfactory reasons for exclusion given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-24 09:29:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Comment: All excluded patients were accounted for and satisfactory reasons for exclusion given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-03-01 06:10:39 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:10:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>Comment: The study's pre-specified outcomes that are of interest to this review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-01 06:10:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>Comment: The study's pre-specified outcomes that are of interest to this review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-08 10:52:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>Comment: The study's pre-specified outcomes that are of interest to this review have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-02-14 08:01:21 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-14 08:01:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Jongste-1989">
<DESCRIPTION>
<P>No additional significant bias concerns.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 15:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monreal-1994">
<DESCRIPTION>
<P>No additional significant bias concerns.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 15:09:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prandoni-2005">
<DESCRIPTION>
<P>No additional significant bias concerns.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-08 13:36:51 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-08 13:36:33 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-09-08 13:27:10 +0100" MODIFIED_BY="[Empty name]">Rutosides versus placebo or no comparator for the treatment of PTS</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>Comparison 1: Rutosides vs placebo or no comparator for the treatment of PTS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>People with post-thrombotic syndrome<BR/>
<B>Setting: </B>
<BR/>
<B>Intervention: </B>Rutosides<BR/>
<B>Comparison: </B>Placebo or no comparator for the treatment of PTS</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo or no comparator for the treatment of PTS</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Rutosides</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Improvement in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 1.29<BR/>(0.69 to 2.41)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>164<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#9711;&#9711;&#9711;<BR/>VERY LOW <SUP>1, 2, 3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>554 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>616 per 1000<BR/>(462 to 750)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>559 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>621 per 1000<BR/>(467 to 754)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Deterioration in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 0.61<BR/>(0.19 to 1.90)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>80<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#9711;&#9711;&#9711;<BR/>VERY LOW <SUP>1, 2, 3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>150 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>97 per 1000<BR/>(32 to 251)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>150 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>97 per 1000<BR/>(32 to 251)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> - no information on blinding of outcome assessors; <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> - non-blinded comparator group</P>
<P>
<SUP>2</SUP> <LINK REF="STD-De-Jongste-1989" TYPE="STUDY">De Jongste 1989</LINK> vs placebo, <LINK REF="STD-Prandoni-2005" TYPE="STUDY">Prandoni 2005</LINK> vs no comparator</P>
<P>
<SUP>3</SUP> Publication bias suspected</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-09-08 13:36:28 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-09-08 13:27:22 +0100" MODIFIED_BY="[Empty name]">Rutosides versus elastic compression stockings for the treatment of PTS</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>Comparison 2: Rutosides versus elastic compression stockings for the treatment of PTS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population:</B>People with post-thrombotic syndrome<BR/>
<B>Setting: </B>
<BR/>
<B>Intervention: </B>Rutosides<BR/>
<B>Comparison: </B>ECS</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with ECS for the treatment of PTS</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Rutosides</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Improvement in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 0.80<BR/>(0.31 to 2.03)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>80<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#10753;&#9711;&#9711;<BR/>LOW <SUP>1, 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>700 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>651 per 1000<BR/>(420 to 826)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>700 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>651 per 1000<BR/>(420 to 826)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Deterioration in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 0.61<BR/>(0.19 to 1.90)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>80<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#10753;&#9711;&#9711;<BR/>LOW <SUP>1, 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>150 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>97 per 1000<BR/>(32 to 251)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>150 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>97 per 1000<BR/>(32 to 251)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> No blinding of treatment groups.</P>
<P>
<SUP>2</SUP> Publication bias suspected</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-09-08 13:36:51 +0100" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2015-09-08 13:27:29 +0100" MODIFIED_BY="[Empty name]">Rutosides versus hidrosmina for the treatment of PTS</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>Comparison 3: Rutosides versus hidrosmina for the treatment of PTS</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>People with post-thrombotic syndrome<BR/>
<B>Setting: </B>
<BR/>
<B>Intervention: </B>Rutosides<BR/>
<B>Comparison: </B>Hidrosmina</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with hidrosmina for the treatment of PTS</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Rutosides</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Improvement in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 0.18<BR/>(0.04 to 0.94)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>29<BR/>(1 RCT) <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#10753;&#9711;&#9711;<BR/>LOW <SUP>1, 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>213 per 1000<BR/>(57 to 585)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>600 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>213 per 1000<BR/>(57 to 585)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>Deterioration in PTS</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>OR 0.19<BR/>(0.01 to 4.24)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>29<BR/>(1 RCT) <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P>&#10753;&#10753;&#9711;&#9711;<BR/>LOW <SUP>1, 2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>133 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>28 per 1000<BR/>(2 to 395)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Moderate</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>133 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>28 per 1000<BR/>(2 to 395)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Open cross-over trial</P>
<P>
<SUP>2</SUP> Publication bias suspected</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-02-14 08:12:04 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-02-11 12:18:48 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Rutosides versus placebo or no comparator for the treatment of PTS</NAME>
<DICH_OUTCOME CHI2="2.914110919743685" CI_END="2.407192969350406" CI_START="0.6907004584480393" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.289437585733882" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="46" I2="65.68421629990816" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3815109062970034" LOG_CI_START="-0.16071025573355535" LOG_EFFECT_SIZE="0.11040032528172403" METHOD="MH" MODIFIED="2012-07-16 11:41:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08780793990964808" P_Q="1.0" P_Z="0.4247968300620678" Q="0.0" RANDOM="NO" SCALE="161.49528230241512" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="83" WEIGHT="100.0" Z="0.7981269510889766">
<NAME>Improvement in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.191602569550327" CI_START="0.9071385442117571" EFFECT_SIZE="2.170138888888889" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="18" LOG_CI_END="0.7153014387118773" LOG_CI_START="-0.04232637954218857" LOG_EFFECT_SIZE="0.33648752958484435" MODIFIED="2012-03-02 15:21:38 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.445034330760623" STUDY_ID="STD-De-Jongste-1989" TOTAL_1="41" TOTAL_2="43" VAR="0.19805555555555557" WEIGHT="39.50617283950617"/>
<DICH_DATA CI_END="1.812477773828919" CI_START="0.2814953590050543" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="28" LOG_CI_END="0.2582726895808857" LOG_CI_START="-0.5505287609373617" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2012-03-02 15:21:49 +0000" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.4750939756661683" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.2257142857142857" WEIGHT="60.49382716049382"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 09:57:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="180.88" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Deterioration in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rutosides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9042312486622726" CI_START="0.19402752673418075" EFFECT_SIZE="0.6078431372549019" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.27971968770373185" LOG_CI_START="-0.7121366522310594" LOG_EFFECT_SIZE="-0.2162084822636637" MODIFIED="2012-03-02 15:25:38 +0000" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.5826213238457627" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.33944760699978915" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 10:04:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="41" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Reduction of oedema/swelling</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0163160626972463" CI_START="0.5345914741939091" EFFECT_SIZE="1.2698412698412698" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="18" LOG_CI_END="0.47947684684413044" LOG_CI_START="-0.2719779717674068" LOG_EFFECT_SIZE="0.10374943753836186" MODIFIED="2011-11-07 16:33:19 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.44140828021376066" STUDY_ID="STD-De-Jongste-1989" TOTAL_1="41" TOTAL_2="42" VAR="0.19484126984126984" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 10:04:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="41" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1401304266423615" CI_START="0.5217617669951012" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.4969476870524179" LOG_CI_START="-0.2825277477566812" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2011-11-07 16:32:57 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.4578677288724956" STUDY_ID="STD-De-Jongste-1989" TOTAL_1="41" TOTAL_2="42" VAR="0.20964285714285713" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 10:00:25 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of DVT/PE</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.56212933664009" CI_START="0.06037870974644056" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2191161718029548" LOG_CI_START="-1.2191161718029548" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-07 15:15:49 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.4322297480788657" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="2.051282051282051" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 10:02:31 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="41" TOTAL_2="42" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rutosides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2647605114140186" CI_START="0.1902286958701251" EFFECT_SIZE="0.6563706563706564" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.3550222840219615" LOG_CI_START="-0.7207239694279173" LOG_EFFECT_SIZE="-0.18285084270297788" MODIFIED="2012-03-02 14:54:48 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.6318986743062943" STUDY_ID="STD-De-Jongste-1989" TOTAL_1="41" TOTAL_2="42" VAR="0.39929593459005225" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-02-11 12:14:43 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Rutosides versus ECS for the treatment of PTS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 09:55:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>ECS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ECS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0330434228593743" CI_START="0.31159494202502075" EFFECT_SIZE="0.7959183673469388" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.3081466546374583" LOG_CI_START="-0.5064096006414873" LOG_EFFECT_SIZE="-0.09913147300201446" MODIFIED="2012-07-04 16:42:49 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.47847437646934543" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.2289377289377289" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-08 09:58:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Deterioration in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>ECS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rutosides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ECS</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9042312486622726" CI_START="0.19402752673418075" EFFECT_SIZE="0.6078431372549019" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.27971968770373185" LOG_CI_START="-0.7121366522310594" LOG_EFFECT_SIZE="-0.2162084822636637" MODIFIED="2012-07-04 16:47:18 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.5826213238457627" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.33944760699978915" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-11 12:14:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="40" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence of DVT/PE</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>ECS</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ECS</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.56212933664009" CI_START="0.06037870974644056" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2191161718029548" LOG_CI_START="-1.2191161718029548" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-04 16:52:07 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="1.4322297480788657" STUDY_ID="STD-Prandoni-2005" TOTAL_1="40" TOTAL_2="40" VAR="2.051282051282051" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-02-14 08:12:04 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Rutosides versus hidrosmina for the treatment of PTS</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-14 08:12:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Hidrosmina</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours hidrosmina</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours rutosides</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9393566903013262" CI_START="0.03519201127855399" EFFECT_SIZE="0.18181818181818182" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.027169467142705066" LOG_CI_START="-1.4535559118457826" LOG_EFFECT_SIZE="-0.7403626894942439" MODIFIED="2013-02-13 15:14:04 +0000" MODIFIED_BY="[Empty name]" ORDER="9" O_E="0.0" SE="0.837866458345363" STUDY_ID="STD-Monreal-1994" TOTAL_1="14" TOTAL_2="15" VAR="0.7020202020202019" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-02-14 08:11:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="179.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Deterioration in PTS</NAME>
<GROUP_LABEL_1>Rutosides</GROUP_LABEL_1>
<GROUP_LABEL_2>Hidrosmina</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rutosides</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours hidrosmina</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.240326099496001" CI_START="0.008176967410017283" EFFECT_SIZE="0.18620689655172415" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6273992570091961" LOG_CI_START="-2.087407733161171" LOG_EFFECT_SIZE="-0.7300042380759876" MODIFIED="2013-02-13 15:19:15 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="1.5946910645374086" STUDY_ID="STD-Monreal-1994" TOTAL_1="14" TOTAL_2="15" VAR="2.5430395913154533" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-09-02 11:16:52 +0100" MODIFIED_BY="Karen Welch">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-09-02 11:16:52 +0100" MODIFIED_BY="Karen Welch" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAALUCAYAAACRji2QAABxn0lEQVR42uydD0Rfb///bzKTJCP5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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-03-04 10:07:27 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUkAAAGvCAIAAABZ9bBgAAATWklEQVR42u3dv44dxRLH8ZWQEMEG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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-07-16 11:41:41 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Rutosides for the treatment of PTS, outcome: 1.1 Improvement in PTS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuwAAACgCAMAAABg+8nwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-09-02 10:14:10 +0100" MODIFIED_BY="Karen Welch">
<APPENDIX ID="APP-01" MODIFIED="2015-09-02 10:14:10 +0100" MODIFIED_BY="Karen Welch" NO="1">
<TITLE MODIFIED="2015-05-20 10:39:30 +0100" MODIFIED_BY="Karen Welch">CRS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-02 10:14:10 +0100" MODIFIED_BY="Karen Welch">
<TABLE COLS="3" ROWS="28">
<TR>
<TD COLSPAN="2">
<P>Search run on Wed Sep 2 2015</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Postthrombotic Syndrome EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>postthrombotic:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>56</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>(post near3 thrombot*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>109</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>PTS:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>4543</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Postphlebitic Syndrome EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>23</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>postphlebit*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>35</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>(post near3 phlebit*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7</P>
</TD>
<TD ALIGN="RIGHT">
<P>4678</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Rutin EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>159</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>*rutoside*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>183</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>*rutin*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>517</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>*ruton*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>59</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>Paroven:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>buckwheat:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>bioflav*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>55</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Quercetin EXPLODE ALL TREES</P>
</TD>
<TD ALIGN="RIGHT">
<P>113</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>*quercetin*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>217</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>MESH DESCRIPTOR Escin</P>
</TD>
<TD ALIGN="RIGHT">
<P>52</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(aesculus* near hippocastan*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(escin* or aescin* or essaven*):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>100</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>rosskastani*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>(horse* near (chestnut or chest-nut)):TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>42</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>venosta*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>20</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>horsechestnut*:TI,AB,KY</P>
</TD>
<TD ALIGN="RIGHT">
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24</P>
</TD>
<TD ALIGN="RIGHT">
<P>1026</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>#8 AND #25</P>
</TD>
<TD ALIGN="RIGHT">
<P>15</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 reports to 3 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;105 reports after duplicates removed screened by TSC from title/abstracts&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 reports identified from searching the CRS&lt;/p&gt;&lt;p&gt;37 records for 33 trials identified from WHO International Clinical Trials Registry&lt;/p&gt;&lt;p&gt;78 records identified from ClinicalTrials.gov&lt;/p&gt;&lt;p&gt;9 records identified from ISRCTN&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified from Specialised Register&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;105 reports not relevant for this review update&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>